Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor*
暂无分享,去创建一个
Dominique Schols | T. Schwartz | M. Rosenkilde | D. Schols | G. Bridger | S. Hatse | Sigrid Hatse | R. Skerlj | Lars-Ole Gerlach | Gary J Bridger | Mette M Rosenkilde | Thue W Schwartz | L. Gerlach | Renato T Skerlj
[1] C. Dunbar,et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. , 2006, Blood.
[2] Dominique Schols,et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. , 2005, Biochemical pharmacology.
[3] Dominique Schols,et al. Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.
[4] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[5] Kasper P. Jensen,et al. Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. , 2003, Biochemistry.
[6] E. Kostenis. Is Gα16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? , 2001 .
[7] E. De Clercq,et al. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. , 2001, Molecular pharmacology.
[8] T. Schwartz,et al. Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor* , 2001, The Journal of Biological Chemistry.
[9] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[10] Edward J. Fuchs,et al. Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers , 2000, Antimicrobial Agents and Chemotherapy.
[11] E. De Clercq,et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. , 1999, Journal of medicinal chemistry.
[12] Thomas N. Kledal,et al. Agonists and Inverse Agonists for the Herpesvirus 8-encoded Constitutively Active Seven-transmembrane Oncogene Product, ORF-74* , 1999, The Journal of Biological Chemistry.
[13] B Clotet,et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. , 1999, Molecular pharmacology.
[14] M. P. Suh,et al. Self-Assembly of Molecular Brick Wall and Molecular Honeycomb from Nickel(II) Macrocycle and 1,3,5-Benzenetricarboxylate: Guest-Dependent Host Structures , 1998 .
[15] M. Malim,et al. Differential regulation of CXCR4 and CCR5 endocytosis. , 1998, Journal of cell science.
[16] Kouji Matsushima,et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.
[17] Masahiko Kuroda,et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.
[18] T. Schwartz,et al. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. , 1998, Molecular pharmacology.
[19] E. Clercq,et al. Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.
[20] J. Albert,et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.
[21] D. Littman,et al. Expression pattern of HIV-1 coreceptors on T cells: implications for viral transmission and lymphocyte homing. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Nishikawa,et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.
[23] E. De Clercq,et al. Synthesis and Structure−Activity Relationships of Phenylenebis(methylene)- Linked Bis-tetraazamacrocycles That Inhibit Human Immunodeficiency Virus Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams , 1996 .
[24] E. De Clercq,et al. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. , 1995, Journal of medicinal chemistry.
[25] R. Pauwels,et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. , 1995, Journal of medicinal chemistry.
[26] E. De Clercq,et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 , 1994, Antimicrobial Agents and Chemotherapy.
[27] E. De Clercq,et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[28] Ronald L. Bruening,et al. Thermodynamic and kinetic data for macrocycle interactions with cations and anions , 1991 .
[29] S. Ho,et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.
[30] M. Berridge,et al. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. , 1983, The Biochemical journal.
[31] L. Sklar,et al. Crystal and molecular structure of di(perchlorato)(1,4,8,11-tetraazacyclotetradecane)copper (II). Cu(cyclam) (ClO4)2 , 1975 .